Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    A Look Ahead In Life Sciences: What We Are Tracking In The First Quarter Of 2025 And Beyond

    To help companies and investors navigate the many evolving and emerging laws and regulations across pharmaceuticals, biologics, medical devices, diagnostics...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Abivax Announces $235.8 Million IPO

    Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Cooley LLP
    Cooley LLP
Article

Accord Receives Positive EMA Opinion For Two Denosumab Biosimilars

On April 2, 2025, Accord received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for two denosumab biosimilars...
United StatesFood, Drugs, Healthcare, Life Sciences
Goodwin Procter LLP
Goodwin Procter LLP
  • Article

    Allorion Therapeutics Announces Exclusive Option, Global License Agreement With AstraZeneca

    Under the terms of the agreement, AstraZeneca will be granted an exclusive option to license a novel EGFR L858R allosteric inhibitor to develop and commercialize globally.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Cooley LLP
    Cooley LLP
  • Article

    Alvotech And Teva Announce FDA Approval Of Additional Presentation For Ustekinumab Biosimilar

    On October 22, 2024, Alvotech and Teva announced that SELARSDI™ (ustekinumab-aekn) received FDA approval for a new presentation, 130 mg/26 mL (5 mg/mL)...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Alvotech Initiates Confirmatory Patient Study For AVT03, A Proposed Denosumab Biosimilar

    Alvotech announced this week the initiation of a confirmatory patient study for AVT03 (denosumab), a biosimilar candidate to PROLIA® and XGEVA®...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Amgen Announces Positive Results For Phase 3 Study Of Ustekinumab Biosimilar

    Amgen recently announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA (ustekinumab) in adult patients with moderate to severe plaque psoriasis.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    APHIS Biotechnology Regulatory Services Reschedules Stakeholder Meeting For February 26, 2026

    The U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) announced on December 16, 2025, that its Biotechnology Regulatory Services...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Bergeson & Campbell
    Bergeson & Campbell
  • Article

    ASCO Updates Policy On Genetic Testing

    The American Society of Clinical Oncology ("ASCO") recently updated its policy statement on genetic and genomic testing for cancer susceptibility...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Attorney Spotlight: Jekkie Kim (Video)

    Meet Dr. Jekkie Kim, a nationally recognized life sciences transactional lawyer who joined WilmerHale as a partner in its Palo Alto office in 2024.
    United StatesFood, Drugs, Healthcare, Life Sciences
    WilmerHale
    WilmerHale
  • Article

    Bill To Fix Sunscreen Ingredient Approval Process Clears The Senate

    The Senate has passed the Sunscreen Innovation Act through a unanimous consent agreement.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Biosimilars Licensing Agreement Updates

    Earlier this week, Biocon Biologics Ltd. announced that it has entered into a strategic out-licensing agreement with Yoshindo Inc. to commercialize ustekinumab and denosumab biosimilars...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    BYOOVIZ® (Ranibizumab-Nuna) Granted Interchangeable Status

    Recently, Biogen and Samsung Bioepis's ranibizumab biosimilar (BYOOVIZ) was granted interchangeable status by the U.S. Food and Drug Administration. BYOOVIZ was deemed interchangeable...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Celltrion And Rani Therapeutics To Jointly Develop Oral Formulation Of Ustekinumab Biosimilar

    Celltrion will exclusively supply CT-P43 to Rani for the non-clinical and phase 1 clinical trials of an oral formulation of ustekinumab with the potential to expand throughout its product pipeline.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Celltrion Announces Commercial Availability Of ZYMFENTRA™ (Infliximab-dyyb)

    Celltrion USA announced on March 18, 2024, the availability of ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Celltrion Submits BLA For Omalizumab Biosimilar

    Last week, Celltrion USA announced it had submitted a BLA for CT-P39, a biosimilar to XOLAIR (omalizumab). Phase 3 studies demonstrated that in patients with chronic spontaneous urticaria...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    CMS Announces Preliminary Gapfill Payments For New Molecular Pathology Codes

    CMS has recently announced a 60-day comment period on gapfill payment amounts for new molecular pathology codes under the Clinical Laboratory Fee Schedule for 2013 and 2014.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    CMS Appoints Ombudsman to Handle Pharmaceutical/Technology Industry Concerns

    James Bailey is the new CMS Medicare Pharmaceutical and Technology Ombudsman, a role Congress established in the 21st Century Cures Act ...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    Coherus Biosciences Announces Approval Of A Pegfilgrastim Autoinjector

    On March 6, 2023, Coherus Biosciences announced FDA approval of an autoinjectable version of Udenyca, Coherus' biosimilar to Amgen's Neulasta (pegfilgrastim).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Deal Watch: Henlius Licenses Rituximab And Trastuzumab Products To Abbott In Brazil

    Earlier this week, Shanghai Henlius Biotech, Inc. announced that it has entered into a semi-exclusive license agreement with Abbott Operations Uruguay S.R.L. for the commercialization of HANLIKANG (rituximab)...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Showing 241–260 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics